glp-1 agonists and inflammation drugs calm beyond diabetes weight loss Anti-inflammatory role of glucagon-like peptide

FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain

The qualifying diagnoses (HFpEF, uncontrolled hypertension, CKD, pre-diabetes, prior MI, prior stroke, PAD) are the conditions where GLP-1 trials have shown direct benefit or strong biological plausibility for benefit

A recent study has shown that people who take such drugs often regain all the weight they have lost within a year of halting the medication

-Arrestins as Important Regulators of Glucose and Energy Homeostasis

doi:10.1158/1078-0432.CCR-04-1725 132

Azevedo Da Silva M, Fournier A, Boutron-Ruault M-C, Balkau B, Bonnet F, Nabi H, et al